Biotechnology
ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies
SAN FRANCISCO, Feb. 8, 2023 /PRNewswire/ -- ReviR Therapeutics, a privately held developer of a suite of small molecule RNA-targeting technologies for cancer and other genetically-defined diseases, and Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing, an...
2023-02-08 22:00
2119
SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center
* The additional investment for the 'R&PD Center' was confirmed by the board of directors committee with a total of261 million USD * SK bioscience plans to establish a vaccine-biopharmaceutical hub, organizing a global cooperative model against new pandemics SEONGNAM, South Korea, Feb. 8, 202...
2023-02-08 20:00
2019
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.
SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointedRegis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, ...
2023-02-08 16:05
2427
Complete Genomics Drops Genome Sequencing Price to Sub $100 at AGBT General Meeting
DNBSEQ-T20×2*produces up to 50,000 WGS per year at a first sub hundred-dollar price per genome DNBSEQ-T7* offers an outstanding $1.5/Gb price for sequencing consumables DNBSEQ-G99* delivers a first-in-class PE150 run within 12 hours with a data output of 8- 48 Gb per run stLFR library prep ...
2023-02-07 22:00
2210
RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 7, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics today announced ...
2023-02-07 16:34
3001
J INTS BIO, Oral TKI 'JIN-A04', poster presentation of HER2 exon20 insertion mutation in NSCLC
SEOUL, South Korea, Feb. 6, 2023 /PRNewswire/ -- J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibitor (TKI) targeting HER2 Exon20 insertion mutation in NSCLC, will be presented at the upcoming 2023 American Cancer Research Association meeting inOr...
2023-02-07 12:23
1362
Thermo Fisher Scientific launches Cell Therapy Collaboration Center Program in Singapore to accelerate therapy development across Asia Pacific
Program supports cell therapy innovators in the development of next-generation, life-saving drugs and therapeutics through every stage of their journey to improve patient outcomes SINGAPORE, Feb. 7, 2023 /PRNewswire/ -- Thermo Fisher Scientific Inc., the world leader in serving science, tod...
2023-02-07 11:00
4884
Tavneos® (avacopan) approved in Australia for the treatment of ANCA-associated vasculitis
First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced the Therapeutic Goods Administration (TGA) i...
2023-02-07 06:00
3478
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
WILMINGTON, Del., Feb. 6, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's inves...
2023-02-06 21:10
1832
Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb
SAN DIEGO, SHANGHAI and SYDNEY, Feb. 6, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announced that the U.S. Food and Drug Administration (FDA) recently granted the initial investigational new drug (IND) application for its drug candidate IMG-008, a long-acting anti-IL-36R antib...
2023-02-06 18:00
2067
Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
* Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstratesclinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; * Clinically meaningful improvements were reported in CRISS (the key compos...
2023-02-06 13:01
1866
Boehringer Ingelheim Philippines is awarded Top Employer for the 5th year in a row
* Boehringer Ingelheim is one of 15 global Top Employers worldwide * Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® * Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition M...
2023-02-06 08:00
2190
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointedRoger Sidhu, M.D., as Chief Medical Officer. Dr. Sidhu is a seasoned lea...
2023-02-03 22:00
5124
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma
BCMA/CD19 dual-targeting FasTCAR-T GC012F has demonstrated deep responses and favorable safety profile in proof of concept clinical studies Company plans to initiate Phase 1b/2 clinical trial in the U.S. in second quarter of 2023 SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb. 3, 2023 /PR...
2023-02-03 20:30
3914
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based inSouth Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, ...
2023-02-03 14:34
2652
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference
BEIJING and TORONTO, Feb. 2, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer,James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Mar...
2023-02-02 19:37
2096
TotalEnergies ENEOS Signs Solar Rooftop Project with Ecolite, a health and wellness company in Malaysia
KUALA LUMPUR, Malaysia, Feb. 2, 2023 /PRNewswire/ -- Ecolite Biotech Manufacturing Sdn Bhd, a health and wellness company inMalaysia, has signed a long-term agreement with TotalEnergies ENEOS to provide a 0.4 megawatt-peak (MWp) solar photovoltaic (PV) system to its facility inMalaysia. Ecolite i...
2023-02-02 10:00
10602
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)
SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Invivoscribe is pleased to announce the appointment ofMasato Sasaki as General Manager of LabPMM GK, our reference laboratory inJapan. Mr. Sasaki brings a wealth of scientific experience with him as he served at Illumina K.K. (Japan) as a leader on their cl...
2023-02-02 05:00
2583
CN Energy Group. Inc. Announces Closing of $10 Million Underwritten Public Offering
LISHUI, China, Feb. 1, 2023 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY", or the "Company") today announced the closing of its previously announced underwritten public offering. The gross proceeds to the Company were approximately$10 million, before deducting underwriting discount...
2023-02-01 22:59
3250
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout inChina expected in 2023 * Top-line data from tanfanercept's Phase 3 dry eye study e...
2023-02-01 20:00
1923
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 275 media titles]
2024-11-29 20:33
Most Read
Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
2024-11-26 13:00
5136
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
3461